Abstract
BackgroundThe goal of the study was to investigate the current clinical practices among oncologic surgeons regarding cytoreductive surgery (CRS) with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC).MethodsFrom September to October 2016, an online questionnaire surveyed the oncologic surgeons by email. The questionnaire included 20 multiple-choice questions of the following: eligibility for the CRS with HIPEC procedure, perioperative staging and surgery skill, assessment of residual tumors, and method used for intraperitoneal HIPEC.ResultsThe response rate was 16% (34/217). The majority of respondents (68%) worked at a university hospital. All respondents indicated that mesenteric invasion is the most crucial factor affecting treatment decision. Most surgeons (79%) used the Sugarbaker’s staging system to intraoperatively measure the extent of peritoneal invasion. The methods used to measure the extent of miliary pattern of residual tumor spread, and the amount of residual tumor after electrocauterization varied among the surgeons. Most responders (65%) used the closed system of HIPEC.ConclusionsDespite the fact that CRS HIPEC is the standard treatment for PSM, the clinical practices are very different according to each clinical situation. Nevertheless, mesenteric invasion was found to be the most important factor impacting the treatment decision-making by the majority of responders.
Highlights
The goal of the study was to investigate the current clinical practices among oncologic surgeons regarding cytoreductive surgery (CRS) with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)
From September to October 2016, an online questionnaire surveyed by the corresponding authors from various countries from published manuscripts on CRS with HIPEC and to the members of the Korean Society of Peritoneal surface malignancies (PSM) (KSPSM)
The questionnaire included 20 multiple-choice questions to assess the opinions of the responders; their criteria for patient selection; and eligibility for CRS with HIPEC, modes of perioperative staging, level of surgery skills, residual tumor assessment, and method used for HIPEC administration
Summary
The goal of the study was to investigate the current clinical practices among oncologic surgeons regarding cytoreductive surgery (CRS) with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC). Yoo et al World Journal of Surgical Oncology (2018) 16:92 adoption, and accessibility associated with CRS/HIPEC remain a significant challenge, even in recent inquiries [7, 8]. A few guidelines have been created to optimize the benefits and minimize the morbidity for patients with PSM [9, 10]. The treatments for PSM are complex and heterogeneous and require institutional support [11]. The standardization of clinical practice guidelines is paramount in improving patient selection, perioperative morbidity, and completeness of cytoreduction [12, 13]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
